Keerthi Shet1, Hikari Yoshihara1, John Kurhanewicz1, Ann Schwartz2, Cliff J. Rosen3, Xiaojuan Li1
1Radiology, University of California, San Francisco, San Francisco, CA, United States; 2Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, United States; 3Jackson Laboratory, Bar Harbor, ME
Clinical 1H-MRS studies have shown that increased bone-marrow adiposity is associated with decreased BMD in patients with osteoporosis/osteopenia. Marrow adipose tissue(MAT) from the C57BL/6J(B6) mice was analyzed using HRMAS-NMR following exposure to type-2-diabetes-drug�rosiglitazone. We observed significant changes in MAT composition along with the rosiglitazone-induced increase in adiposity. In particular, the decreased unsaturated-lipids and increased saturated-lipids may be correlated with decreased bone strength with rosiglitazone treatment. Thus, consistent with recent observation in-vivo that decreased MAT unsaturation level is associated with fracture-risk, the fatty-acid unsaturation/saturation level of MAT can be a potential imaging marker for bone quality and fracture.